These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 3044273)

  • 81. Evaluation of the nephrotoxicity of iproplatin (CHIP) in comparison to cisplatin by the measurement of urinary enzymes.
    Pendyala L; Madajewicz S; Lele SB; Arbuck SG; Creaven PJ
    Cancer Chemother Pharmacol; 1985; 15(3):203-7. PubMed ID: 4053265
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Cisplatin-induced vomiting depends on circadian timing.
    Kobayashi M; To H; Tokue A; Fujimura A; Kobayashi E
    Chronobiol Int; 2001 Sep; 18(5):851-63. PubMed ID: 11763992
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Kallikrein and renal enzyme excretion in rats.
    Raab W; Killer S
    Arzneimittelforschung; 1976; 26(1):100. PubMed ID: 947165
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Follow-up study of enzymuria and beta 2 microglobulinuria during cis-platinum treatment.
    Tirelli AS; Colombo N; Cavanna G; Mangioni C; Assael BM
    Eur J Clin Pharmacol; 1985; 29(3):313-8. PubMed ID: 3908127
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Changes in urinary excretion of endothelin-1-like immunoreactivity in patients with testicular cancer receiving high-dose cisplatin therapy.
    Takeda M; Komeyama T; Tsutsui T; Mizusawa T; Go H; Hatano A; Tanikawa T
    Am J Kidney Dis; 1994 Jul; 24(1):12-6. PubMed ID: 8023817
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Administration of gallium nitrate by continuous infusion: lack of chronic nephrotoxicity confirmed by studies of enzymuria and beta 2-microglobulinuria.
    Leyland-Jones B; Bhalla RB; Farag F; Williams L; Coonley CJ; Warrell RP
    Cancer Treat Rep; 1983 Oct; 67(10):941-2. PubMed ID: 6354440
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Urinary 28-kD calbindin-D as a new marker for damage to distal renal tubules caused by cisplatin-based chemotherapy.
    Takashi M; Zhu Y; Miyake K; Kato K
    Urol Int; 1996; 56(3):174-9. PubMed ID: 8860739
    [TBL] [Abstract][Full Text] [Related]  

  • 88. [Urinary N-acetyl-beta-D-glucosaminidase activity in liver cirrhosis with renal impairment].
    Amakasu H; Kanno A; Abe M; Sato K; Goto Y
    Nihon Shokakibyo Gakkai Zasshi; 1991 Jan; 88(1):51-6. PubMed ID: 2027251
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Supplemental fosfomycin and/or steroids that reduce cisplatin-induced nephrotoxicity.
    Umeki S; Watanabe M; Yagi S; Soejima R
    Am J Med Sci; 1988 Jan; 295(1):6-10. PubMed ID: 2827472
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Urinary protein and enzyme excretion in patients receiving chemotherapy with the cis-platinum analogs carboplatin (CBDCA, JM8) and iproplatin (CHIP, JM9).
    Skillen AW; Buamah PK; Cantwell BM; Cornell C; Hodson AW; Harris AL
    Cancer Chemother Pharmacol; 1988; 22(3):228-34. PubMed ID: 3044631
    [TBL] [Abstract][Full Text] [Related]  

  • 91. [Cisplatin nephrotoxicity: clinical observation and animal experiment].
    Qiu XF; Li ZX
    Zhonghua Fu Chan Ke Za Zhi; 1992 Jan; 27(1):35-7, 59. PubMed ID: 1505276
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Urinary beta 2-microglobulin: early indicator of high dose cisdiamminedichloroplatinum nephrotoxicity? Influence of furosemide.
    de Gislain C; Dumas M; d'Athis P; Lautissier JL; Escousse A; Guerrin J
    Cancer Chemother Pharmacol; 1986; 18(3):276-9. PubMed ID: 3542269
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Increased nephrotoxicity of combination taxol and cisplatin chemotherapy in gynecologic cancers as compared to cisplatin alone.
    Merouani A; Davidson SA; Schrier RW
    Am J Nephrol; 1997; 17(1):53-8. PubMed ID: 9057954
    [TBL] [Abstract][Full Text] [Related]  

  • 94. [Comparative study on external use of mercury-containing preparation badu shengji san in sensitive monitoring indicators of induced early renal injury].
    Lu Y; He R; Xu Q; Peng B; Li J
    Zhongguo Zhong Yao Za Zhi; 2012 Mar; 37(6):706-10. PubMed ID: 22715704
    [TBL] [Abstract][Full Text] [Related]  

  • 95. [Perioperative renal functions in patients with chronic renal disease].
    Sugai Y; Sugai K; Aoki H
    Masui; 1992 Jul; 41(7):1140-4. PubMed ID: 1495182
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Protective effects of fosfomycin on cisplatin-induced nephrotoxicity in patients with lung cancer.
    Rojanasthien N; Kumsorn B; Atikachai B; Leotrakul S; Thongprasert S
    Int J Clin Pharmacol Ther; 2001 Mar; 39(3):121-5. PubMed ID: 11396752
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Early measurement of urinary N-acetyl-β-glucosaminidase helps predict severe hyponatremia associated with cisplatin-containing chemotherapy.
    Arakawa Y; Tamura M; Sakuyama T; Aiba K; Eto S; Yuda M; Tanaka Y; Matsumoto A; Nishikawa K
    J Infect Chemother; 2015 Jul; 21(7):502-6. PubMed ID: 25851853
    [TBL] [Abstract][Full Text] [Related]  

  • 98. [High sensitive photometric assay of pancreatic lipase and clinical investigation of urinary lipase in patients with various histopathological types of primary glomerulonephritis].
    Soezima A; Yomogida S; Suzuki M; Tuzi M; Nakabayasi K; Kitamoto K; Nagasawa T
    Nihon Jinzo Gakkai Shi; 1990 Oct; 32(10):1103-7. PubMed ID: 2287102
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Study of lead exposure from automobile exhaust as a risk for nephrotoxicity among traffic policemen.
    Mortada WI; Sobh MA; El-Defrawy MM; Farahat SE
    Am J Nephrol; 2001; 21(4):274-9. PubMed ID: 11509798
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Renal tubular function in patients treated with high-dose cisplatin.
    Daugaard G; Abildgaard U; Holstein-Rathlou NH; Bruunshuus I; Bucher D; Leyssac PP
    Clin Pharmacol Ther; 1988 Aug; 44(2):164-72. PubMed ID: 2840230
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.